Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

REEDER, C. B ; REECE, D. E ; ZEPEDA, Vhj ; MIKHAEL, J. R ; LEIS, J. F ; BERGSAGEL, P. L ; FONSECA, R ; STEWART, A. K ; KUKRETI, V ; CHEN, C ; TRUDEL, S ; HENTZ, J ; NOBLE, B ; PIROOZ, N. A ; SPONG, J. E ; PIZA, J. G

Leukemia, 2009-07, Vol.23 (7), p.1337-1341 [Periódico revisado por pares]

Avenel, NJ: Nature Publishing Group

Texto completo disponível